Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Subscribe To Our Newsletter & Stay Updated